Taiwan: Vetnostrum Animal Health Reports Strong 2026 Sales as Company Expands Across Asia

Taiwan-listed Vetnostrum Animal Health (TWSE: 6936) is positioning itself for another year of expansion across Asia, supported by growth in veterinary pharmaceuticals, vaccines, feed additives and companion-animal products.

Vetnostrum held an investor conference on August 25, while its latest reported quarterly figures show NT$375.66 million in revenue and NT$39.41 million in net income, with EPS of NT$0.54.

Growth story increasingly international

The company operates across swine, poultry, ruminants, pets and aquaculture, with products spanning veterinary medicines, vaccines, feed additives and animal-health services.

Its international strategy is particularly relevant as Asian livestock producers face continuing demand for vaccination, disease prevention, productivity enhancement and companion-animal healthcare.

Vetnostrum has previously identified expansion across Asia as a strategic priority. Taiwan’s stock exchange noted that the company intends to strengthen production capacity, innovation and its presence across the Asia-Pacific animal-health market.

Revenue trajectory

The company’s FY2025 revenue reached NT$1.416 billion, compared with NT$1.294 billion in 2024, representing approximately 9.4% growth. FY2025 net income was NT$128.85 million.

The latest monthly data also indicate continued momentum: July 2026 revenue was NT$145.6 million, up 13.09% year on year, while cumulative January–July revenue reached approximately NT$889.6 million, up 11.63%.

Analyst view

The strategic opportunity for Vetnostrum lies less in Taiwan’s relatively small domestic market and more in its ability to use Taiwan as a manufacturing, R&D and regulatory platform for Southeast Asian and wider Asian markets.

Poultry and swine vaccines, veterinary pharmaceuticals, feed additives and pet-health products provide multiple growth avenues, while geographic diversification can reduce dependence on any single livestock market.

However, the 65% H1 net-profit growth, NT$1.2–1.4 billion H1 revenue range and NT$400–450 million full-year profit guidance supplied in the brief should be treated as management/earnings-call claims until reconciled with the company’s formal financial filings. The independently accessible financial databases reviewed currently show the latest quarterly revenue at NT$375.66 million and net income at NT$39.41 million.

Bottom Line

Vetnostrum is becoming an interesting Asian animal-health company to watch as Taiwan’s listed veterinary-pharmaceutical sector develops from a domestic base toward a more export-oriented regional model.